1383727-17-0|SC-2001|5-Bromo-2-[4-methoxy-5-(2H-pyrrol-2-ylidenemethyl)-1H-pyrrol-2-yl]-1H-indole|-范德生物科技公司

SC-2001

NMR下载 COA and HPLC MSDS下载
names：
5-Bromo-2-[4-methoxy-5-(2H-pyrrol-2-ylidenemethyl)-1H-pyrrol-2-yl]-1H-indole
CAS号：
1383727-17-0
MDL Number：
MF(分子式)： C18H14BrN3O MW(分子量)： 368.234
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	5-Bromo-2-[4-methoxy-5-(2H-pyrrol-2-ylidenemethyl)-1H-pyrrol-2-yl]-1H-indole
英文别名	SC-2001; SC 2001; SC2001.
CAS号	1383727-17-0
SMILES	COC1=C(/C=C2N=CC=C/2)NC(C(N3)=CC4=C3C=CC(Br)=C4)=C1
Inchi	InChI=1S/C18H14BrN3O/c1-23-18-10-16(22-17(18)9-13-3-2-6-20-13)15-8-11-7-12(19)4-5-14(11)21-15/h2-10,21-22H,1H3/b13-9+
InchiKey	MJCQSMDIFFNYRS-UKTHLTGXSA-N
分子式 Formula	C18H14BrN3O
分子量 Molecular Weight	368.234
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	SC-2001(CAS:1383727-17-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	SC-2001 is a MCL-1 inhibitor. SC-2001 is an Obatoclax analog that inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18;8(29):46801-46817. doi: 10.18632/oncotarget.8695. PubMed PMID: 27086916; PubMed Central PMCID: PMC5564524.

[2]Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis. 2014 Dec;35(12):2807-14. doi: 10.1093/carcin/bgu210. Epub 2014 Oct 16. PubMed PMID: 25322871.

[3] Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. Neoplasia. 2014 Jul;16(7):595-605. doi: 10.1016/j.neo.2014.06.005. Epub 2014 Jul 18. PubMed PMID: 25047655; PubMed Central PMCID: PMC4198826.

[4] Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget. 2014 Jul 15;5(13):4909-19. PubMed PMID: 24952874; PubMed Central PMCID: PMC4148109.

[5] Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells. Breast Cancer Res Treat. 2014 Jul;146(1):71-84. doi: 10.1007/s10549-014-3000-0. Epub 2014 Jun 6. PubMed PMID: 24903225.

6: Chen KF, Lin JP, Shiau CW, Tai WT, Liu CY, Yu HC, Chen PJ, Cheng AL. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol. 2012 Aug 1;84(3):268-77. doi: 10.1016/j.bcp.2012.04.023. Epub 2012 May 9. PubMed PMID: 22580047.7: Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation. Cancer Lett. 2012 Aug 1;321(1):27-35. doi: 10.1016/j.canlet.2012.03.023. Epub 2012 Mar 28. PubMed PMID: 22465052.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开